Drugs With Cardiotoxicity Flashcards

1
Q

Main drag cuisine cardiotoxicity

A

Cytotoxic drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Type of cytotoxic drugs with cardiotoxicity effect

A
Anthracyclines 
Taxoids
5-fluorouracil
Cisplatin
Trastuzumab
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Anthracycline Cardiotoxicity effects

A

Cardiomyopathy
congestive heart failure
ECG alterations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Early onset effects of anthracyclines occur within

A

1year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In children for anthracyclines which one is more common late onset or early onset clinical cardiotoxicity

A

Late onset more frequent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Risk factors for anthracycline induced cardiotoxicity

A
Cumulative dose
age 
Concominent administration with other chemotherapeutics
 underlying heart disease 
previous Radiotherapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Most important risk factor for cardiotoxicity in anthracycline

A

Cumulative dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Dose of the doxorubicin that can create cardiomyopathy and congestive heart failure

A

450-550 (normal is between 60-75 every 3 weeks )

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which anthracycline has a lower frequency of cardiotoxicity at therapeutic dose
epirubicin or doxorubicin?

A

Epirubicin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Mechanism of toxicity of Anthracyclien

A

Free radicals and superoxide formation
Semiquinone radical forms complex with iron -> anthracycline-iron free radicals complex -> reduces O2 -> superoxide production -> lipid peroxidation

Apoptosis

Calcium homeostasis disruption

Immunogenicity rxn

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Monitoring and markers of cardiotoxicity

A

Echocardiogram identify myocardial dysfunction

Endomyocardial biopsy - Measure the presence and extent of fibrosis

Troponin t indicates myocardial cell damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Prevention/treatment of anthracyclines induced cardiotoxicity

A

Cumulative dose imitations

Antioxidants ( not a success)

Iron chelators (Dexrazoxane - slow IV or fast infusion before treatment )

Lipid lowering agents

Liposomal drugs formulation of anthracyclines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Type of taxoids

A

Paclitaxel

Docetaxel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cardiotoxic effects of paclitaxel

A
Brady  arrythmias 
Tachyarrythmias 
AV block
Cardiac ischemia 
Hypotension 
Congestive heart failure (especially when combined with doxorubicin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Risk factors of taxoid induced cardio toxicity

A

Unstable angina
Severe coronary heart diseases
Congestive heart failure
Atrial fibrillation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

When is paclitaxel safe to administer with cardiac risk factors

A

Single therapy

17
Q

Paclitaxel drug solubility enhancer name

A

Ctenophor El

18
Q

Mechanism of toxicity of taxoids

A

Ctenophor El causes massive histamine release

Damage via subcellular organelles

Pharmacokinetic interaction with doxorubicin (over 380). Paclitaxel decreases its hepatic elimination

19
Q

What should you do if you administer taxoids with anthracycline

A

Lower cumulative dose of anthracyclien

20
Q

5 fluorouracil cardiotoxicith mostly occur with what form of administrions

A

Continuous infusion

21
Q

Cardiotoxic effects of 5FU

A

Cardiac arrythmias
Silent myocardial ischemia
Congestive heart failure

22
Q

Risk factors of 5FU

A

Coronary artery disease

Concurrent radiotherapy

23
Q

5FU MOA

A
Unclear 
Vasospasm leading to ischemia 
Direct toxicity on myocardium 
Activation of coagulation system 
Thrombosis of coronary artery 
Immunoallergic
24
Q

Cyclophosohamide and ifosfamide alkylation agents MOA

A

Increase in free oxygen radicals

25
Q

Cisplatin cardiotoxic symptoms

A

Acute myocardial infarction

26
Q

Cisplatin MOA

A

Vascular damage
Altered platelet aggregation
Hypomagnesemia
Arachidonic pathway activation